NewLimit has raised $435 million in a Series C financing to advance its first-in-human cell age reprogramming therapy targeting liver cells. The company’s stated plans are to start Phase I clinical testing next year, with initial enrollment focused on fatty liver disease. The funding follows faster-than-expected scientific progress after a lead liver candidate emerged from its screening platform by the end of last year, after the company previously expected multi-year maturation. At roughly a $3B+ valuation as described in the provided materials, the round underscores continuing investor appetite for cellular reprogramming strategies positioned as potentially disease-modifying rather than symptomatic interventions.